Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.43 |
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17799764 | 0.82 | TAS1R3 (0.52) | MEN1GAARAB9AKMT2A | |
| SCHEMBL17799663 | 0.82 | AKT1 (0.48) | F10F2MEN1GAAHTT | |
| SCHEMBL17799731 | 0.82 | TSHR (0.54) | MEN1GAAHTTRAB9AKMT2A | |
| SCHEMBL16220951 | 0.79 | L3MBTL1 (0.57) | F10MEN1RAB9AKMT2A | |
| SCHEMBL17799645 | 0.78 | GAA (0.44) | F10MEN1GAARAB9AKMT2A | |
| SCHEMBL30477654 | 0.78 | DPP4 (0.49) | MEN1GAARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL22437488 | 0.78 | DPP4 (0.49) | MEN1GAARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL17806038 | 0.78 | DPP4 (0.49) | MEN1GAARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL16372319 | 0.78 | DPP4 (0.49) | MEN1GAARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL27441418 | 0.78 | DPP4 (0.49) | MEN1GAARAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50724-E1 | 4-membered ring carboxamides used as nematicides | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-06 | — | — | US | disclosed |
| EP-3019476-B1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| US-9867371-B2 | 4-membered ring carboxamides used as nematicides | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | TUBA3C, DDT, CYCS | F10 4392/4885F2 4346/4885MEN1 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.